Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

NCT01889797 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

32

Enrollment

OTHER

Sponsor class

Stopped Closed due prolonged enrollment timelines

Conditions

Indolent Non-Hodgkin's Lymphoma

Interventions

BIOLOGICAL: Arm A: Rituximab
BIOLOGICAL: Arm B: GA101

Sponsor

PrECOG, LLC.

Collaborators

[object Object]